Who are Lucemyra's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Neurontin, Iopidine, Dipivefrin, Sudafed, Catapres-Tts-1, Naphcon Forte.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lofexidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Lucemyra — Competitive Intelligence Brief

Lucemyra (LOFEXIDINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: lofexidine. Area: Neuroscience.

marketed lofexidine Alpha-2A adrenergic receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Lucemyra (LOFEXIDINE) — Biocorrx Pharms. Lucemyra works by activating the alpha-2A adrenergic receptor to reduce the release of norepinephrine, a neurotransmitter involved in withdrawal symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lucemyra TARGET	LOFEXIDINE	Biocorrx Pharms	marketed	lofexidine	Alpha-2A adrenergic receptor	2018-01-01
Neurontin	gabapentin	Generic (originally Parke-Davis/Pfizer)	marketed	Gabapentinoid (anticonvulsant/neuropathic pain agent)	Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor	1993-12-30
Iopidine	APRACLONIDINE	Harrow Health	marketed	alpha-Adrenergic Agonist	Alpha-2A adrenergic receptor	1987-01-01
Dipivefrin	dipivefrine	AbbVie	marketed	Adrenergic Receptor Agonist	Alpha-2A adrenergic receptor	1980-01-01
Sudafed	pseudoephedrine	Generic (multiple manufacturers)	marketed	Nasal decongestant (sympathomimetic)	Alpha-1A adrenergic receptor, Alpha-2A adrenergic receptor, Beta-2 adrenergic receptor	1976-01-01
Catapres-Tts-1	CLONIDINE	Lavipharm	marketed	Central alpha-2 Adrenergic Agonist	Alpha-2A adrenergic receptor	1974-01-01
Naphcon Forte	NAPHAZOLINE	Novartis	marketed	Non-Standardized Chemical Allergen [EPC]	Alpha-2A adrenergic receptor	1971-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-04-17 — Catapres-Tts-1 · 8337890 · Formulation · US
2031-09-08 — Catapres-Tts-1 · 8623409 · Formulation · US

Sponsor landscape (lofexidine class)

Biocorrx Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lucemyra — Competitive Intelligence Brief. https://druglandscape.com/ci/lofexidine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab